Wyszuk. zaawans.

Tom 7, Nr 1 (2022)
Artykuł przeglądowy
Opublikowany online: 2022-02-10

dostęp otwarty

Pokaż PDF (angielski) Pobierz plik PDF
Wyświetlenia strony 5216
Wyświetlenia/pobrania artykułu 226
Pobierz cytowanie

Eksport do Mediów Społecznościowych

Eksport do Mediów Społecznościowych

The Poly(ADP-ribose) polymerase inhibitors in pancreatic cancer

Katarzyna Zubik1, Julia Talaśka1, Dawid Sigorski23, Sergiusz Nawrocki34
Biuletyn Polskiego Towarzystwa Onkologicznego Nowotwory 2022;7(1):34-43.

Streszczenie

Genome instability and mutations are the hallmarks of cancer. Mutations within BRCA genes increase the risk of pancreatic cancer (PC) development. Poly(ADP-ribose) polymerase inhibitors (PARPi) show the synthetic lethality phenomenon in tumoral cells with BRCA mutation and improve outcomes in patients with breast, prostate and ovarian cancer. Olaparib was the first PARPi registered for the patient with metastatic PC with a deleterious or suspected deleterious germline BRCA-mutation. The POLO phase III clinical trial shows that olaparib in PC increases progression-free survival, however it does not prolong the overall survival. Currently, many clinical trials are ongoing to determine the clinical utility of PARPi in monotherapy or polytherapy of PC. The role of PARPi in PC has not been well established and many questions remain unanswered. This review aims to summarise the rationales behind the use of PARPi and current clinical data.

Słowa kluczowe: PARP inhibitorsolaparibpancreatic cancerBRCA mutation

Artykuł dostępny w formacie PDF

Pokaż PDF (angielski) Pobierz plik PDF

Referencje

  1. Society. AC. Facts & Figures 2021. American Cancer Society.
  2. Ducreux M, Cuhna ASa, Caramella C, et al. ESMO Guidelines Committee. Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015; 26 Suppl 5: v56–v68.
    CrossRefPubMed
  3. Springfeld C, Jäger D, Büchler MW, et al. Chemotherapy for pancreatic cancer. Presse Med. 2019; 48(3 Pt 2): e159–e174.
    CrossRefPubMed
  4. Piątek M, Nawrocki S. Locally advanced pancreatic cancer — new therapeutic challenges. Nowotwory. Journal of Oncology. 2016; 66(4): 312–316.
    CrossRef
  5. Aguilar-Quesada R, Muñoz-Gámez JA, Martín-Oliva D, et al. Modulation of transcription by PARP-1: consequences in carcinogenesis and inflammation. Curr Med Chem. 2007; 14(11): 1179–1187.
    CrossRefPubMed
  6. Martínez-Bosch N, Fernández-Zapico ME, Navarro P, et al. Poly(ADP-Ribose) Polymerases: New Players in the Pathogenesis of Exocrine Pancreatic Diseases. Am J Pathol. 2016; 186(2): 234–241.
    CrossRefPubMed
  7. Sigorski D, Iżycka-Świeszewska E, Bodnar L. Poly(ADP-Ribose) Polymerase Inhibitors in Prostate Cancer: Molecular Mechanisms, and Preclinical and Clinical Data. Target Oncol. 2020; 15(6): 709–722.
    CrossRefPubMed
  8. Pujade-Lauraine E, Ledermann J, Selle F, et al. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2017; 18(9): 1274–1284.
    CrossRef
  9. Coleman RL, Sill MW, Bell-McGuinn K, et al. A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation - An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol. 2015; 137(3): 386–391.
    CrossRefPubMed
  10. Litton JK, Rugo HS, Ettl J, et al. Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation. N Engl J Med. 2018; 379(8): 753–763.
    CrossRefPubMed
  11. Mateo J, Porta N, Bianchini D, et al. Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial. Lancet Oncol. 2020; 21(1): 162–174.
    CrossRefPubMed
  12. Doraczyńska-Kowalik A, Janus-Szymańska G, Matkowski R, et al. Genetyka i onkologia (część 2.). Podstawy medycyny personalizowanej w leczeniu raka piersi i raka jajnika. Nowotwory. Journal of Oncology. 2020; 70(5): 187–202.
    CrossRef
  13. Food and Drug Administration. FDA approves olaparib for gBRCAm metastatic pancreatic adenocarcinoma. 2020.
  14. Golan T, Hammel P, Reni M, et al. Maintenance Olaparib for Germline -Mutated Metastatic Pancreatic Cancer. N Engl J Med. 2019; 381(4): 317–327.
    CrossRefPubMed
  15. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011; 144(5): 646–674.
    CrossRefPubMed
  16. Goral V. Pancreatic Cancer: Pathogenesis and Diagnosis. Asian Pac J Cancer Prev. 2015; 16(14): 5619–5624.
    CrossRefPubMed
  17. Hu C, Hart SN, Polley EC, et al. Association Between Inherited Germline Mutations in Cancer Predisposition Genes and Risk of Pancreatic Cancer. JAMA. 2018; 319(23): 2401–2409.
    CrossRefPubMed
  18. Bailey P, Chang DK, Nones K, et al. Australian Pancreatic Cancer Genome Initiative. Genomic analyses identify molecular subtypes of pancreatic cancer. Nature. 2016; 531(7592): 47–52.
    CrossRefPubMed
  19. Waddell N, Pajic M, Patch AM, et al. Australian Pancreatic Cancer Genome Initiative. Whole genomes redefine the mutational landscape of pancreatic cancer. Nature. 2015; 518(7540): 495–501.
    CrossRefPubMed
  20. Rondinelli B, Gogola E, Yücel H, et al. EZH2 promotes degradation of stalled replication forks by recruiting MUS81 through histone H3 trimethylation. Nat Cell Biol. 2017; 19(11): 1371–1378.
    CrossRefPubMed
  21. Chaudhuri AR, Callen E, Ding X, et al. Replication fork stability confers chemoresistance in BRCA-deficient cells. Nature. 2016; 535(7612): 382–387.
    CrossRef
  22. Li X, Heyer WD. Homologous recombination in DNA repair and DNA damage tolerance. Cell Res. 2008; 18(1): 99–113.
    CrossRefPubMed
  23. Moynahan ME, Jasin M. Mitotic homologous recombination maintains genomic stability and suppresses tumorigenesis. Nat Rev Mol Cell Biol. 2010; 11(3): 196–207.
    CrossRefPubMed
  24. Lohse I, Kumareswaran R, Cao P, et al. Effects of Combined Treatment with Ionizing Radiation and the PARP Inhibitor Olaparib in BRCA Mutant and Wild Type Patient-Derived Pancreatic Cancer Xenografts. PLoS One. 2016; 11(12): e0167272.
    CrossRefPubMed
  25. Pilarski R. The Role of Testing in Hereditary Pancreatic and Prostate Cancer Families. Am Soc Clin Oncol Educ Book. 2019; 39: 79–86.
    CrossRefPubMed
  26. Yadav S, Kasi PM, Bamlet WR, et al. Effect of Germline Mutations in Homologous Recombination Repair Genes on Overall Survival of Patients with Pancreatic Adenocarcinoma. Clin Cancer Res. 2020; 26(24): 6505–6512.
    CrossRefPubMed
  27. Golan T, Kanji ZS, Epelbaum R, et al. Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers. Br J Cancer. 2014; 111(6): 1132–1138.
    CrossRefPubMed
  28. Lowery MA, Jordan EJ, Basturk O, et al. Real-Time Genomic Profiling of Pancreatic Ductal Adenocarcinoma: Potential Actionability and Correlation with Clinical Phenotype. Clin Cancer Res. 2017; 23(20): 6094–6100.
    CrossRefPubMed
  29. Southey MC, Goldgar DE, Winqvist R, et al. Australian Ovarian Cancer Study Group. PALB2, CHEK2 and ATM rare variants and cancer risk: data from COGS. J Med Genet. 2016; 53(12): 800–811.
    CrossRefPubMed
  30. Sehdev A, Gbolahan O, Hancock BA, et al. Germline and Somatic DNA Damage Repair Gene Mutations and Overall Survival in Metastatic Pancreatic Adenocarcinoma Patients Treated with FOLFIRINOX. Clin Cancer Res. 2018; 24(24): 6204–6211.
    CrossRefPubMed
  31. Lord C, Ashworth A. BRCAness revisited. Nature Reviews Cancer. 2016; 16(2): 110–120.
    CrossRef
  32. Holter S, Borgida A, Dodd A, et al. Germline BRCA Mutations in a Large Clinic-Based Cohort of Patients With Pancreatic Adenocarcinoma. J Clin Oncol. 2015; 33(28): 3124–3129.
    CrossRefPubMed
  33. Chaffee KG, Oberg AL, McWilliams RR, et al. Prevalence of germ-line mutations in cancer genes among pancreatic cancer patients with a positive family history. Genet Med. 2018; 20(1): 119–127.
    CrossRefPubMed
  34. Nanda N, Roberts NJ. Serine/Threonine Kinase and its Role in Pancreatic Risk. Genes (Basel). 2020; 11(1).
    CrossRefPubMed
  35. Roberts NJ, Jiao Y, Yu J, et al. ATM mutations in patients with hereditary pancreatic cancer. Cancer Discov. 2012; 2(1): 41–46.
    CrossRefPubMed
  36. Grant RC, Selander I, Connor AA, et al. Prevalence of germline mutations in cancer predisposition genes in patients with pancreatic cancer. Gastroenterology. 2015; 148(3): 556–564.
    CrossRefPubMed
  37. Mandelker D, Zhang L, Kemel Y, et al. Mutation Detection in Patients With Advanced Cancer by Universal Sequencing of Cancer-Related Genes in Tumor and Normal DNA vs Guideline-Based Germline Testing. JAMA. 2017; 318(9): 825–835.
    CrossRefPubMed
  38. Ayars M, Eshleman J, Goggins M. Susceptibility of ATM-deficient pancreatic cancer cells to radiation. Cell Cycle. 2017; 16(10): 991–998.
    CrossRefPubMed
  39. Wang Y, Kuramitsu Y, Tokuda K, et al. Gemcitabine induces poly (ADP-ribose) polymerase-1 (PARP-1) degradation through autophagy in pancreatic cancer. PLoS One. 2014; 9(10): e109076.
    CrossRefPubMed
  40. Perkhofer L, Schmitt A, Romero Carrasco MC, et al. ATM Deficiency Generating Genomic Instability Sensitizes Pancreatic Ductal Adenocarcinoma Cells to Therapy-Induced DNA Damage. Cancer Res. 2017; 77(20): 5576–5590.
    CrossRefPubMed
  41. Lord CJ, Ashworth A. PARP inhibitors: Synthetic lethality in the clinic. Science. 2017; 355(6330): 1152–1158.
    CrossRefPubMed
  42. McCabe N, Turner NC, Lord CJ, et al. Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition. Cancer Res. 2006; 66(16): 8109–8115.
    CrossRefPubMed
  43. Marteijn JA, Lans H, Vermeulen W, et al. Understanding nucleotide excision repair and its roles in cancer and ageing. Nat Rev Mol Cell Biol. 2014; 15(7): 465–481.
    CrossRefPubMed
  44. Li GM. DNA Mismatch Repair and the DNA Damage Response. Encyclopedia of Biological Chemistry. 2013: 51–53.
    CrossRef
  45. Wong W, Raufi AG, Safyan RA, et al. BRCA Mutations in Pancreas Cancer: Spectrum, Current Management, Challenges and Future Prospects. Cancer Manag Res. 2020; 12: 2731–2742.
    CrossRefPubMed
  46. Plummer R. Perspective on the pipeline of drugs being developed with modulation of DNA damage as a target. Clin Cancer Res. 2010; 16(18): 4527–4531.
    CrossRefPubMed
  47. Lee MV, Katabathina VS, Bowerson ML, et al. BRCA-associated Cancers: Role of Imaging in Screening, Diagnosis, and Management. Radiographics. 2017; 37(4): 1005–1023.
    CrossRefPubMed
  48. Peralta-Leal A, Rodríguez MI, Oliver FJ. Poly(ADP-ribose)polymerase-1 (PARP-1) in carcinogenesis: potential role of PARP inhibitors in cancer treatment. Clin Transl Oncol. 2008; 10(6): 318–323.
    CrossRefPubMed
  49. Virág L. Structure and function of poly(ADP-ribose) polymerase-1: role in oxidative stress-related pathologies. Curr Vasc Pharmacol. 2005; 3(3): 209–214.
    CrossRefPubMed
  50. Otto H, Reche PA, Bazan F, et al. In silico characterization of the family of PARP-like poly(ADP-ribosyl)transferases (pARTs). BMC Genomics. 2005; 6: 139.
    CrossRefPubMed
  51. de Murcia JM, Niedergang C, Trucco C, et al. Requirement of poly(ADP-ribose) polymerase in recovery from DNA damage in mice and in cells. Proc Natl Acad Sci U S A. 1997; 94(14): 7303–7307.
    CrossRefPubMed
  52. Martínez-Bosch N, Iglesias M, Munné-Collado J, et al. Parp-1 genetic ablation in Ela-myc mice unveils novel roles for Parp-1 in pancreatic cancer. J Pathol. 2014; 234(2): 214–227.
    CrossRefPubMed
  53. Hou Z, Cui Y, Xing H, et al. Down-expression of poly(ADP-ribose) polymerase in p53-regulated pancreatic cancer cells. Oncol Lett. 2018; 15(2): 1943–1948.
    CrossRefPubMed
  54. Wang M, Wu W, Wu W, et al. PARP-1 and Ku compete for repair of DNA double strand breaks by distinct NHEJ pathways. Nucleic Acids Res. 2006; 34(21): 6170–6182.
    CrossRefPubMed
  55. Pilié PG, Tang C, Mills GB, et al. State-of-the-art strategies for targeting the DNA damage response in cancer. Nat Rev Clin Oncol. 2019; 16(2): 81–104.
    CrossRefPubMed
  56. Dedes KJ, Wilkerson PM, Wetterskog D, et al. Synthetic lethality of PARP inhibition in cancers lacking BRCA1 and BRCA2 mutations. Cell Cycle. 2011; 10(8): 1192–1199.
    CrossRefPubMed
  57. Xu F, Sun Y, Yang SZ, et al. Cytoplasmic PARP-1 promotes pancreatic cancer tumorigenesis and resistance. Int J Cancer. 2019; 145(2): 474–483.
    CrossRefPubMed
  58. Toma M, Skorski T, Śliwiński T. Synthetic lethality as a functional tool in basic research and in anticancer therapy. Postepy Hig Med Dosw. 2014; 68: 1091–1103.
    CrossRef
  59. Bryant HE, Schultz N, Thomas HD, et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature. 2005; 434(7035): 913–917.
    CrossRefPubMed
  60. Farmer H, McCabe N, Lord CJ, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature. 2005; 434(7035): 917–921.
    CrossRefPubMed
  61. Klauschen F, von Winterfeld M, Stenzinger A, et al. High nuclear poly-(ADP-ribose)-polymerase expression is prognostic of improved survival in pancreatic cancer. Histopathology. 2012; 61(3): 409–416.
    CrossRefPubMed
  62. Gonçalves A, Finetti P, Sabatier R, et al. Poly(ADP-ribose) polymerase-1 mRNA expression in human breast cancer: a meta-analysis. Breast Cancer Res Treat. 2011; 127(1): 273–281.
    CrossRefPubMed
  63. Kaufman B, Shapira-Frommer R, Schmutzler RK, et al. Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation. J Clin Oncol. 2015; 33(3): 244–250.
    CrossRefPubMed
  64. Golan T, Varadhachary G, Sela T, et al. Phase II study of olaparib for BRCAness phenotype in pancreatic cancer. J Clin Oncol. 2018; 36(4_suppl): 297–297.
    CrossRef
  65. Golan T, Hammel P, Reni M, et al. Overall survival from the phase 3 POLO trial: Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer. J Clin Oncol. 2021; 39(3_suppl): 378–378.
    CrossRef
  66. Reiss KA, Mick R, O'Hara MH, et al. Phase II Study of Maintenance Rucaparib in Patients With Platinum-Sensitive Advanced Pancreatic Cancer and a Pathogenic Germline or Somatic Variant in , , or . J Clin Oncol. 2021; 39(22): 2497–2505.
    CrossRefPubMed
  67. Lowery MA, Kelsen DP, Capanu M, et al. Phase II trial of veliparib in patients with previously treated BRCA-mutated pancreas ductal adenocarcinoma. Eur J Cancer. 2018; 89: 19–26.
    CrossRefPubMed
  68. Matulonis UA, Monk BJ. PARP inhibitor and chemotherapy combination trials for the treatment of advanced malignancies: does a development pathway forward exist? Ann Oncol. 2017; 28(3): 443–447.
    CrossRefPubMed
  69. O'Reilly EM, Lee JW, Lowery MA, et al. Phase 1 trial evaluating cisplatin, gemcitabine, and veliparib in 2 patient cohorts: Germline BRCA mutation carriers and wild-type BRCA pancreatic ductal adenocarcinoma. Cancer. 2018; 124(7): 1374–1382.
    CrossRefPubMed
  70. O'Reilly EM, Lee JW, Zalupski M, et al. Randomized, Multicenter, Phase II Trial of Gemcitabine and Cisplatin With or Without Veliparib in Patients With Pancreas Adenocarcinoma and a Germline Mutation. J Clin Oncol. 2020; 38(13): 1378–1388.
    CrossRefPubMed
  71. Nevala-Plagemann C, Hidalgo M, Garrido-Laguna I. From state-of-the-art treatments to novel therapies for advanced-stage pancreatic cancer. Nat Rev Clin Oncol. 2020; 17(2): 108–123.
    CrossRefPubMed
  72. Tempero MA, Malafa MP, Al-Hawary M, et al. Pancreatic Adenocarcinoma, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2021; 19(4): 439–457.
    CrossRefPubMed
  73. Takeuchi S, Doi M, Ikari N, et al. Mutations in BRCA1, BRCA2, and PALB2, and a panel of 50 cancer-associated genes in pancreatic ductal adenocarcinoma. Sci Rep. 2018; 8(1): 8105.
    CrossRefPubMed

Informacje o plikach cookie

Niezbędne pliki cookie

Zawsze aktywne

Te pliki cookie są niezbędne do prawidłowego wyświetlania i działania strony internetowej. Zablokowanie ich może spowodować nieprawidłowe działanie strony.

Analityczne pliki cookie

W ramach naszej strony internetowej korzystamy z narzędzi analitycznych, takich jak Google Analytics, które umożliwiają nam weryfikację ruchu na stronie internetowej. Narzędzia te mogą wymagać użycia plików cookie.

Społecznościowe pliki cookie

Są to pliki cookie powiązane z portalami społecznościowymi, z których korzystamy. Zaakceptowanie ich pozwoli na powiązanie Twojej wizyty na stronie z naszymi profilami w mediach społecznościowych.

Marketingowe pliki cookie

Są to pliki cookie odpowiedzialne za prowadzenie działań reklamowych i marketingowych - zgoda na ich wykorzystanie pozwoli nam kierować do Ciebie reklamy, bazujące na podstawie Twoich wcześniejszych aktywności w ramach naszej stronie internetowej.

Copyright © 2023-2024 Via Medica Regulamin Polityka cookies Polityka prywatności Nota prawna